Glycolysis hypothesis is also supported by the findings that glycolysis inhibitor apatinib (which also has other effects such as vascular endothelial growth factor [VEGF] receptor 2 inhibition, Akt inhibition, and GSK3 reactivation) significantly reduces ovarian cancer masses both in vitro and in mouse transplants in vivo [85]. The gene discussed is AKT1; the disease is ovarian carcinoma.